Kobayashi Pharmaceutical Co (4967) AI Stock Analysis

• Market Cap: $394.84B
• Dividend Yield: 1.93%
• Average Volume (3M): 155.22K
• Price to Earnings (P/E): 33.5
• Beta (1Y): 0.27
• Revenue Growth: -6.64%
• EPS Growth: -13.78%
• Country: JP
• Employees: 3,615
• Sector: Consumer Defensive
• Sector Strength: 49
• Industry: Household & Personal Products
• EPS (TTM): 20.75
• Shares Outstanding: 78,050,000
• 10 Day Avg. Volume: 140,290
• 30 Day Avg. Volume: 155,220
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 2.05
• Enterprise Value/Gross Profit: 4.00
• Enterprise Value/Ebitda: 14.03
• 1Y Price Target: $5,091.90
• Price Target Upside: -4.36% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 57 Neutral
• Price Target: ¥5,570.00 ▲(4.62% Upside)

Kobayashi Pharmaceutical's overall stock score is primarily influenced by its strong balance sheet, which is offset by challenges in profitability and cash flow. The technical analysis indicates mixed signals, and the valuation suggests the stock may be overvalued. The absence of earnings call and corporate events data limits further insights.

Kobayashi Pharmaceutical Co Business Overview & Revenue Model

Company Description

Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company provides products in the areas of healthcare, skincare, body warmer, and household. It also offers Ammeltz, a topical analgesic; Inochi no Haha, a women's health medicine; Shirt Coola, a summer cooling spray for cloths; Sarasaty lingerie soap; Bluelet Decoral, a toilet bowl cleaner and freshener; Nightmin Nasal Respiration Tape; Naishitol, a Chinese medicine; Eaude Muge, a medicated lotion for preventing acne; Itoyoji, a dental floss pick; BreathCare, an oral breath freshener capsule; Eybon, an eye wash; Netsusama sheet, a cooling gel sheet for forehead; and Sawaday, a toilet air freshener. Additionally, the company manufactures and sells pharmaceuticals, quasi-drugs, cosmetics, hygiene and paper products, health foods, and processed synthetic resin products; markets nutritional supplements and skin care products through sales promotional campaigns, such as advertising and direct mail; and sells skincare products, health foods, and other items through e-commerce channels. Further, it engages in transportation, real estate management, and advertising planning and production businesses. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.

How the Company Makes Money

Kobayashi Pharmaceutical Co., Ltd. generates revenue primarily through the sale of its over-the-counter (OTC) medications, household products, and personal care goods. The company markets a diverse portfolio of products that target everyday health and hygiene needs, such as cold remedies, pain relief medications, and skin care solutions. It also engages in the development and sale of health supplements. The company's revenue model is driven by its strong distribution network, brand recognition, and its ability to consistently launch innovative products that meet consumer demands. Additionally, strategic partnerships and collaborations may also play a role in expanding its market reach and enhancing its product offerings.

Kobayashi Pharmaceutical Co Financial Statement Overview

Summary

Kobayashi Pharmaceutical has a strong balance sheet with low debt and high equity, but faces challenges with declining net profit margin and negative free cash flow, indicating pressure on profitability and cash flow management.

Income Statement

Kobayashi Pharmaceutical has demonstrated stable revenue generation with a moderate gross profit margin of around 53% for 2024. However, there is a notable decline in net profit margin from 11.7% in 2023 to 6.1% in 2024, indicating pressure on profitability. The revenue growth rate was negative at -4.53% from 2023 to 2024, signaling a contraction. EBIT and EBITDA margins are reasonably healthy but show slight declines, reflecting increased operational challenges.

Balance Sheet

The company maintains a strong balance sheet with a very low debt-to-equity ratio of 0.004, reflecting minimal leverage risk. The equity ratio remains robust at approximately 80.4%, indicating strong financial stability and shareholder equity. Return on equity (ROE) has decreased to 4.7% in 2024, reflecting reduced net income relative to equity.

Cash Flow

Free cash flow has turned negative in 2024, a significant drop from the positive free cash flow of 4.79 billion yen in 2023, signaling cash flow challenges. The operating cash flow to net income ratio remains positive, indicating that operating activities are still generating sufficient cash relative to net income, but free cash flow to net income ratio is negative, highlighting concerns over capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	161.72B	165.60B	173.46B	166.26B	155.25B	150.51B
Gross Profit	82.98B	87.60B	96.38B	92.33B	88.77B	85.27B
EBITDA	23.66B	32.73B	33.65B	33.33B	32.49B	30.76B
Net Income	10.71B	10.07B	20.34B	20.02B	19.71B	19.20B
Balance Sheet
Total Assets	251.75B	265.37B	267.47B	255.83B	252.55B	238.37B
Cash, Cash Equivalents and Short-Term Investments	67.28B	65.75B	79.84B	104.53B	109.05B	94.34B
Total Debt	789.00M	846.00M	987.00M	792.00M	630.00M	688.00M
Total Liabilities	44.69B	51.90B	62.66B	57.93B	56.95B	55.78B
Stockholders Equity	207.06B	213.47B	204.82B	197.90B	195.60B	182.58B
Cash Flow
Free Cash Flow	0.00	-14.81B	4.79B	15.69B	18.23B	19.84B
Operating Cash Flow	0.00	11.25B	18.36B	31.91B	22.42B	23.99B
Investing Cash Flow	0.00	-18.41B	-19.58B	-14.31B	7.99B	-12.66B
Financing Cash Flow	0.00	-7.77B	-19.46B	-20.76B	-10.38B	-6.02B

Kobayashi Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5324.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4967, the sentiment is Negative. The current price of 5324 is below the 20-day moving average (MA) of 5409.90, below the 50-day MA of 5345.88, and below the 200-day MA of 5509.41, indicating a bearish trend. The MACD of 17.35 indicates Positive momentum. The RSI at 42.80 is Neutral, neither overbought nor oversold. The STOCH value of 17.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4967.

Kobayashi Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$20.44B	14.73	-2.84%	3.14%	2.04%	-6.12%
4967	57 Neutral	$394.84B	33.55	5.72%	1.93%	-6.64%	-13.78%
KOSCF	―	$2.21B	109.93	1.11%	3.16%	―	―
LIOPF	―	$2.91B	21.10	7.29%	2.99%	―	―
PCCOF	―	$1.89B	12.39	8.19%	―	―	―
PORBF	―	$1.94B	45.02	3.99%	5.45%	―	―
RPHCF	―	$3.97B	14.54	13.33%	1.27%	―	―